WallStSmart

AbbVie Inc (ABBV)vsTactile Systems Technology Inc (TCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 18460% more annual revenue ($61.16B vs $329.52M). ABBV leads profitability with a 6.9% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

TCMD

Buy

58

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 6.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$211.32

$47.90 premium

UndervaluedFair: $163.42Overvalued
TCMDUndervalued (+55.5%)

Margin of Safety

+55.5%

Fair Value

$62.14

Current Price

$22.50

$39.64 discount

UndervaluedFair: $62.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

TCMD2 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

TCMD4 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$536.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

PEG RatioValuation
17.792/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : TCMD

The strongest argument for TCMD centers on Price/Book, Revenue Growth. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : TCMD

The primary concerns for TCMD are P/E Ratio, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABBV profiles as a value stock while TCMD is a growth play — different risk/reward profiles.

TCMD carries more volatility with a beta of 0.99 — expect wider price swings.

TCMD is growing revenue faster at 21.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 58/100). TCMD offers better value entry with a 55.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Tactile Systems Technology Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.

Want to dig deeper into these stocks?